Medication info
Linagliptin Metformin Duo Tablet 2.5/1000mg

Linagliptin Metformin Duo Tablet 2.5/1000mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanmi Pharm. Co., Ltd.
Appearance
Bright pink, double-sided, convex oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201902372 · Approved 2019.04.17 · Insurance code 649105920

Summary

Main use
Improvement of glycemic control in type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).

Ingredients

Manufacturer
Hanmi Pharm. Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes

View approved original text

This medication is prescribed to help patients with type 2 diabetes who require combined therapy with linagliptin and metformin for better blood sugar control. It helps effectively manage blood sugar levels when used in conjunction with dietary and exercise regimens, making it suitable for individuals struggling with blood sugar management. It is used in the treatment process to improve blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).

Precautions

This medication can cause a serious side effect known as lactic acidosis, so it should not be used in patients with significantly impaired kidney function or poor liver function. Additionally, it should not be administered to type 1 diabetes patients or those with diabetic ketoacidosis or diabetic pre-coma. It is safer not to use this medication during acute illnesses such as severe infections, dehydration, heart failure, or acute myocardial infarction. Women who are pregnant or breastfeeding should avoid taking this medication, and those planning pregnancy should consult their doctor. Patients taking this medication may experience symptoms of hypoglycemia, so blood sugar levels should be closely monitored, especially when taken with insulin or sulfonylurea class drugs. Elderly patients with reduced kidney function should undergo regular kidney function tests and may require dosage adjustments. When iodine contrast agents are administered during surgical or radiological examinations, this medication should be temporarily discontinued before and after the examination, resuming only after kidney function has stabilized. This medication may cause skin conditions such as acute pancreatitis or blistering dermatitis, so if abdominal pain or skin blisters occur, inform a doctor immediately. Long-term use may lead to vitamin B12 deficiency, so if anemia or neurological symptoms occur, vitamin B12 levels should be checked. There may be interactions with other medications taken alongside this one, so it's important to inform your doctor or pharmacist about any other medications being used. It is not recommended for children and adolescents under 10 years old, as safety and efficacy have not been established. The impact on driving or operating machinery is not known, so caution is advised. In case of overdose, there is a risk of lactic acidosis; if side effects occur, seek medical attention immediately.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 100 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • anxiety
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • diabetic neuropathy
  • headache
  • sensory disturbance
  • postherpetic neuralgia
  • hemiparesis
  • syncope
  • drowsiness
  • chest discomfort
  • asthenia
  • epistaxis
  • oropharyngeal pain
  • speech impairment
  • nasal hemorrhage
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • osteoarthritis
  • limb pain
  • pruritus
  • insomnia
  • confusional state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container when in use. Additionally, it is best to store it at room temperature between 1 to 30 degrees Celsius, avoiding extremely hot or cold places.

Appearance and packaging

Appearance

Bright pink, double-sided, convex oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.